Ymmunobio
Basel
About Ymmunobio
Ymmunobio is a preclinical-stage oncology biotech startup committed to creating advanced cancer patient treatments. It makes extensive progress in developing antibodies that have an influence on the immune system by reinstating its immune response to cancers or directly inhibiting cancer cell proliferation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.4M
- Funding stage: Seed
- Last round: Grant (Nov 2024)
- Website: ymmunobio.com
Industries & Categories
Biotechnology, Medical, Product Research
Canonical: https://fsome.com/organization/ymmunobio-76749 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.